Reducing the time and cost of clinical tests will help us beat the big killers, then guide our personalised rejuvenation programmes
It's surprising how much pharmaceutical research to date has been more art than science. Computing power is still a long way off predicting the properties of proteins and cells from their DNA, so until then the more research that can be accelerated by automation (e.g. lab robots, lab-on-chip) the better.
And this is being driven by the big pharma companies who can't afford the failure rate at late stage drug development, or worse after release which can result in multi-billion law suits. I attended an excellenty talk by the chief scientific office for GE Healthcare recently and they are mass producing stem cell lines, and the machinery to test them, so that drugs can be tested for cardio-toxicity much earlier on in the development process.
Click on resource name for more details.
LabGenius: a company for automating the discovery of new antibodies
Wired - 09-Aug-2023
Pioneering a new era of medical technology to speed up drug developmentRead more...
Automating genetics research: A robotic system for handling C. elegans (with video)
Phys.org - 06-Jul-2023
WormPicker takes on time-consuming tasks including inspection, movement between petri dishes and genetic crossingRead more...
MHRA-trial of new robot that can grow stem cells- to bring new low cost and safe therapies
GOV.UK - 16-Mar-2023
Fully automated Intelligent Cell Processing System to manufacture potentially life-saving treatmentsRead more...
£500K in 4th round funding to scale-up Magnitude Biosciences' C. elegans research services
Magnitude Biosciences - 14-Nov-2022
Advances in AI is great, but this sort of automation is what will create the data it needs to find new longevity drugsRead more...
Drones tested as faster means of transport for supplies within a hospital site
BBC - 22-Oct-2022
NHS Trust will carry out further development to see how drones can improve services for its patientsRead more...